Medix Biochemica, a specialist in critical IVD raw materials, has acquired 100% of the shares of myPOLS Biotec.
As a result of the acquisition, Medix Biochemica broadens its portfolio of molecular diagnostic raw materials for the in vitro diagnostics (IVD) industry, complements its scientific expertise and strengthens its local presence in Western Europe.
myPOLS Biotec will form a significant part of the newly established Molecular Diagnostics Business Unit within Medix Biochemica Group, and its high-quality operations will continue in Konstanz, Germany. All founders of myPOLS Biotec will remain involved in the business following the acquisition.
Steve Ferguson, CEO of Medix Biochemica, said: “This acquisition is a great step towards our vision to be the first-choice, independent raw material partner for the IVD industry, and it further accelerates Medix Biochemica’s growth in molecular diagnostics reagents business which is a key strategic expansion area for us. The broad portfolio of myPOLS Biotec, including unique and innovative molecular diagnostics reagents, complements Medix Biochemica’s existing molecular diagnostics offering. With myPOLS technology, we enable customers to shorten their assay development time and complexity and perform molecular testing directly from crude samples. We will offer more flexibility in assay development by partnering in custom development projects. We are excited about the opportunity to offer these molecular diagnostics products to our global customer base.”
Dr. Ramon Kranaster, CEO of myPOLS Biotec, added: “We are thrilled to join Medix Biochemica Group. We are looking forward to contributing to the strong growth of Medix Biochemica and we appreciate its clear focus on quality and R&D. The high scientific competence of the myPOLS team including best-in-class DNA polymerases, supports Medix Biochemica’s long term vision and focus on IVD customers’ needs.”
